Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LEXX 
Lexaria Bioscience Corp (LEXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: LEXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.25% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.43M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 0.86 | 52 Weeks Range 0.77 - 3.39 | Updated Date 09/16/2025 |
52 Weeks Range 0.77 - 3.39 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2155.41% |
Management Effectiveness
Return on Assets (TTM) -84.74% | Return on Equity (TTM) -152.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20918217 | Price to Sales(TTM) 41.28 |
Enterprise Value 20918217 | Price to Sales(TTM) 41.28 | ||
Enterprise Value to Revenue 33.96 | Enterprise Value to EBITDA -7.22 | Shares Outstanding 19559200 | Shares Floating 16946268 |
Shares Outstanding 19559200 | Shares Floating 16946268 | ||
Percent Insiders 7.13 | Percent Institutions 11.75 |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. was founded in 2014. It focuses on drug delivery platforms, particularly DehydraTECHu2122, for improved bioavailability and speed of onset of active pharmaceutical ingredients.
Core Business Areas
- DehydraTECHu2122 Technology Platform: Lexaria's core offering is its patented DehydraTECHu2122 technology, which enhances the way active pharmaceutical ingredients (APIs) enter the bloodstream, promoting faster absorption and higher bioavailability.
- Research and Development: Lexaria conducts research and development activities related to its DehydraTECHu2122 technology, exploring its potential applications in various therapeutic areas, including hypertension, nicotine replacement, and dementia.
- Licensing and Partnerships: Lexaria licenses its DehydraTECHu2122 technology to other companies for use in their products, generating revenue through licensing agreements.
Leadership and Structure
Chris Bunka is the CEO of Lexaria Bioscience Corp. The organizational structure comprises scientific, research, and management teams focused on development, intellectual property, and partnerships.
Top Products and Market Share
Key Offerings
- DehydraTECHu2122: DehydraTECHu2122 is Lexaria's key technology platform. It enhances the oral bioavailability of active pharmaceutical ingredients. There's limited publicly available information on specific market share or revenue directly attributable to this product, as it's primarily licensed to other companies. Competitors include companies offering alternative drug delivery systems like lipid nanoparticles, liposomes, and microencapsulation techniques, but those are for a different set of drugs with different use-cases.
Market Dynamics
Industry Overview
The pharmaceutical industry is continuously seeking improved drug delivery methods to enhance efficacy, reduce dosage, and minimize side effects. There's a growing demand for technologies that improve bioavailability and speed of onset, especially for oral medications.
Positioning
Lexaria positions itself as a technology provider, offering its DehydraTECHu2122 platform to pharmaceutical and consumer product companies. Its competitive advantage lies in its patented technology and demonstrated ability to improve drug absorption.
Total Addressable Market (TAM)
The TAM for improved drug delivery technologies is substantial, estimated to be in the billions of dollars annually, depending on the therapeutic area. Lexaria is positioned to capture a portion of this market by licensing its DehydraTECHu2122 platform to companies developing oral medications.
Upturn SWOT Analysis
Strengths
- Patented DehydraTECHu2122 technology
- Potential for improved drug bioavailability
- Multiple therapeutic applications
- Licensing revenue model
- Focused R&D
Weaknesses
- Limited commercial product portfolio
- Reliance on licensing agreements
- Small market capitalization
- Potential for competition from alternative drug delivery systems
- Dependence on future licensing success
Opportunities
- Expanding licensing agreements
- Developing internal drug products
- Collaborations with pharmaceutical companies
- New therapeutic applications for DehydraTECHu2122
- Increasing awareness of bioavailability challenges
Threats
- Competition from established drug delivery technologies
- Regulatory hurdles for new drug formulations
- Failure of clinical trials
- Patent infringement
- Market acceptance of DehydraTECHu2122
Competitors and Market Share
Key Competitors
- Cara Therapeutics (CARA)
Competitive Landscape
Lexaria competes with companies offering alternative drug delivery systems. Its advantage lies in its patented DehydraTECHu2122 technology. A disadvantage is its smaller size and limited commercial product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on obtaining licensing agreements and securing research funding. There is not a consistent growth trend.
Future Projections: Future growth is projected to be driven by the expansion of DehydraTECHu2122 licensing agreements and potential development of internal drug products.
Recent Initiatives: Recent initiatives include ongoing research and development of DehydraTECHu2122 for various therapeutic applications and actively seeking new licensing partners.
Summary
Lexaria Bioscience Corp. is a biotechnology company focused on improving drug delivery through its DehydraTECHu2122 technology. Its strength lies in its patented technology and potential for enhancing drug bioavailability. However, it is heavily reliant on licensing agreements and faces competition from established drug delivery systems. Future success depends on expanding licensing partnerships and successfully developing internal drug products. The company needs to increase its revenue to remain in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. website
- SEC filings
- Third-party market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2006-10-10 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.